Skin-Related Complications of Insulin Therapy: Epidemiology and Emerging Management Strategies

American Journal of Clinical Dermatology

Volumn 4, Issue 10, 2003, Pages 661-667

  Richardson, Tristan ^a   Kerr, David ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INSULIN; INSULIN ASPART; INSULIN LISPRO; ISOPHANE INSULIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; DESENSITIZATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; LIPOATROPHY; LIPOHYPERTROPHY; LIPOLYSIS; LIPOSUCTION; PATIENT EDUCATION; PRIORITY JOURNAL; PRURITUS; REVIEW; SCAR FORMATION; SHOCK; SIDE EFFECT; SKIN ABSCESS; SKIN DISEASE; URTICARIA; WEIGHT GAIN;

DIABETES MELLITUS; DRUG HYPERSENSITIVITY; HUMANS; INSULIN; LIPODYSTROPHY; SKIN DISEASES;

EID: 0242550882     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304100-00001     Document Type: Review

References (54)

1. Scherbaum WA. Insulin therapy in Europe. Diabetes Metab Res Rev 2002; 18 Suppl. 3: S50-6
2. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000; 23 (9): 1278-83
3. Centers for Disease Control and Prevention. Diabetes trends: diabetes and gestational diabetes trends among adults in the United States, behavioral risk factor surveillance system, 1995 [online]. Available from URL: http://www.cdc.gov/ diabetes/statistics/maps/map6.htm [Accessed 23 July 2003]
4. Centers for Disease Control and Prevention. Diabetes trends: diabetes and gestational diabetes trends among adults in the United States, behavioral risk factor surveillance system, 2000 [online]. Available from URL: http://www.cdc.gov/ diabetes/statistics/maps/map9.htm [Accessed 23 July 2003]
5. Wilson RM, Douglas CA, Tatershall RB, et al. Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins. Diabeologia 1985; 28: 667-70
6. McNally PG, Jowett NI, Kurinczuk JJ, et al. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J 1988; 64 (757): 850-3
7. Murao S, Hirata K, Ishida T, et al. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37 (12): 1031-3
8. Mu L, Goldman JM. Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus. Endocr Pract 2000; 6 (2): 151-2
9. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy [letter]. Diabetes Care 2001; 24: 174
10. Edidin DV. Cutaneous manifestations of diabetes mellitus in children. Pediatr Dermatol 1985; 2: 161-79
11. Reeves WG, Allen BR, Tatershall RB. Insulin-induced lipoatrophy: evidence for an autoimmune pathogenesis. BMJ 1980; 1: 1500-3
12. Raile K, Noelle V, Landgraf R, et al. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001; 109 (8): 393-6
13. Valenta LJ, Elias AN. Insulin induced lipodystrophy in diabetic patients resolved by treatment with human insulin. Ann Intern Med 1985; 102: 790-1
14. Galloway JA, Bressler R. Insulin treatment in diabetes, Med Clin North Am 1978; 1: 983-8
15. Kumar D, Miller L, Mehtalia S. Use of dexamethasone in treatment of insulin lipodystrophy. Diabetes 1977; 26: 296-9
16. Chantelau E, Reuter M, Schotes S, et al. Severe lipoatrophy with human insulin: successfully treated by CSII. Diabet Med 1993; 10 (6): 580-1
17. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104 (2): 106-10
18. Young RJ, Hannan WT, Frier BM, et al. Diabetic Lipohypertrophy delays insulin absorption. Diabetes Care 1984; 7: 479-80
19. Turner BC, Heijlesen OK, Kerr D, et al. Impaired absorption and omission of insulin: a novel method of detection using the diabetes advisory system computer model. Diabetes Technol Ther 2001; 3 (1): 99-109
20. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro. Diabet Med 1998; 15 (12): 1063-4
21. Samdal F, Amland PF, Sandsmark M, et al. Diabetic lipohypertrophy treated with suction-assisted lipectomy. J Intern Med 1993; 234 (5): 489-92
22. Galloway JA, Fireman P, Fineberg SE. Complications of insulin therapy: a brief review of four years experience with human insulin (rDNA). In: Church J, editor. Diabetes mellitus: achievements and scepticism. Royal Society of Medicine International Congress and Symposium series, vol 77. Oxford: Oxford University Press, 1984: 55-64
23. Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4: 189-200
24. Granic M, Renar IP, Metelko Z, et al. Insulin allergy. Diabetes Care 1986; 9: 99-100
25. Menoscal A, Lavarello A, Garcia de los Rios M. Anaphylactic shock due to highly purifies porcine insulin. Rev Med Chil 1986; 114 (10): 969-72
26. Soto-Aguilar MC, de-Shazo RD, Waning NP. Anaphylaxis. Postgrad Med 1987; 82: 154-70
27. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine and bovine insulins in diabetic subjects. Diabetes Care 1982; 5 (2): 119-25
28. Kumar D, Rosenquist RJ, Parameswaran V. Insulin allergy: reaginic antibodies to insulin and pro-insulin. J Clin Endocrinol Metab 1979; 49: 252-4
29. Feinglos MN, Jegasothy BV. "Insulin" allergy due to zinc. Lancet 1979; I (8108): 122-4
30. Lee AY, Chey WY, Choi J, et al. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82 (2): 114-7
31. Dykewicz MS, Kim HW, Orfan N, et al. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol 1994; 93 (1): 117-25
32. Bollinger ME, Hamilton RG, Wood RA. Protamine allergy as a complication of insulin hypersensitivity: a case report. J Allergy Clin Immunol 1999; 194 (2): 462-5
33. DeShazo RD, Boehm TM, Kumar D, et al. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histology. J Allergy Clin Immunol 1982; 69: 229-37
34. Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003; 26 (1): 253-4
35. Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24 (11): 2008-9
36. Grammer LC, Chen PY, Patterson R. Evaluation and management of insulin allergy. J Allergy Clin Immunol 1983; 71: 250-4
37. Witters LE, Ottman JL, Weir GC, et al. Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am J Med 1977; 63: 703-9
38. Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001; 18: 514-6
39. Naf S, Esmatjes E, Reccasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25 (3): 634-5
40. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
41. Boland EA, Grey M, Oesterle A, et al. A "new" way to lower risk of severe hypoglycaemia, improve metabolic control and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-84
42. Van Faassen, Razenberg PPA, Simoons-Smit AM, et al. Carriage of staphylococcus aureus and inflamed infusion sites with insulin pump therapy. Diabetes Care 1989; 12: 153-5
43. Guinn TS, Bailey GJ, Mecklenberg RS. Factors related to discontinuation of subcutaneous insulin infusion therapy. Diabetes Care 1988; 11: 46-51
44. Mecklenberg RS, Benson EA, Benson Jr JW, et al. Acute complications associated with insulin pump therapy: report of experience with 161 patients. JAMA 1984; 252: 3265-9
45. Wickline CL, Cornitus TG, Butler T. Cellulitus caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin infusion pump therapy. Southern Med J 1989; 82: 1432-4
46. Chantelau E, Spraul M, Muhlhauser I, et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetolgia 1989; 32: 421-6
47. Chantelau E, Lange G, Sonnenberg GE, et al. Acute cutaneous complications and catheter needle colonization during insulin pump treatment. Diabetes Care 1987; 10: 478-82
48. Anderson JA, Adkinson NF. Allergic reactions to drugs and biologic agents. JAMA 1987; 258: 2891-9
49. Swift B, Hawkins PN, Richards C, et al. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 2002; 19: 881-2
50. Dische FE, Wernstedt C, Westermark GT, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 1988; 31: 158-61
51. Wheatley T, Edwards OM. Insulin oedema and its clinical significance: metabolic studies in three cases. Diabet Med 1985; 2: 400-4
52. Hopkins DFC, Cotton SJ, Williams G. Effective treatment of insulin-induced oedema using ephedrine. Diabetes Care 1993; 16: 1026-8
53. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-5
54. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol Ther 2002; 4 (2): 157-61